Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Severe and critically ill patients will be enrolled in the study (50 patients) after duly filled consent forms. Recipients shall be divided in to 5 groups with 10 patients per group to compare clinical efficacy and safety of patients in clinical phase I/phase II study. Each group shall receive particular single dose of Intravenously administered Immunoglobulins (IVIG) developed from convalescent plasma of recovered COVID-19 individual , an experimental drug along with standard treatment except for control group which will receive standard treatment only.
Description: All cause mortality of participants will be monitored for 28 days to assess the safety and efficacy of IVIG treatment.
Measure: 28 Days mortality Time: 28 daysDescription: Number of days required for invasive or non-invasive oxygen supply during hospital stay as per oxygen saturation status of patient
Measure: Requirement of supplemental oxygen support Time: 28 daysDescription: Number of days a participant will be requiring assisted ventilation both invasive and noninvasive
Measure: Number of days on assisted ventilation Time: 28 daysDescription: Shifting from ICU to ward
Measure: Days to step down Time: 28 daysDescription: Duration from day of enrollment in study to Day of hospital discharge
Measure: Days to Hospital Discharge Time: 28 daysDescription: Kidney failure, hypersensitivity with cutaneous or hemodynamic manifestations, aseptic meningitis, hemolytic anemia, leuko-neutropenia, transfusion related acute lung injury (TRALI)
Measure: Adverse events during hospital stay Time: 28 daysDescription: Change in C-Reactive Protein (CRP) levels from baseline will be used to monitor inflammation
Measure: Change in C-Reactive Protein (CRP) levels Time: 28 daysDescription: change in neutrophil lymphocyte ratio from baseline will be used to monitor inflammation
Measure: Change in neutrophil lymphocyte ratio Time: 28 daysDescription: change in Ferritin level from baseline will be used to monitor inflammation and immune dysregulation
Measure: Change in Ferritin levels Time: 28 daysDescription: change in LDH from baseline will be used to monitor infections and tissue health
Measure: Change in lactate dehydrogenase (LDH) levels Time: 28 daysDescription: Any change seen in radiological chest X-ray findings
Measure: Change in radiological (X-ray) findings Time: 28 daysDescription: Time taken for participant to receive negative COVID-19 PCR test
Measure: Days to negative SARS-CoV-2 Polymerase Chain Reaction (PCR) test Time: 28 daysDescription: Anti-SARS-CoV-2 antibody titre from blood measured by semi-qualitative method
Measure: Anti-SARS-CoV-2 Antibody Time: 28 daysDescription: Change in body temperature from baseline will be used to monitor safety and efficacy
Measure: Change in fever Time: 28 daysDescription: Change in electrolytes (Sodium) seen in participants
Measure: Change in Sodium levels Time: 28 daysDescription: Change in electrolytes (Potassium) seen in participants
Measure: Change in Potassium levels Time: 28 daysDescription: Change in electrolytes (Chloride) seen in participants
Measure: Change in Chloride levels Time: 28 daysDescription: Change in electrolytes (Bicarbonate) seen in participants
Measure: Change in Bicarbonate levels Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports